Department of Laboratory Medicine

Wayne Leslie Chandler, M.D.

Professor, Laboratory Medicine
School of Medicine
University of Washington

Date Appointed:

2001

Qualifications

M.D., St Louis Univ School of Medicine, 1982

Certification

American Board of Pathology in Clinical Pathology, November 1986

Professional Memberships

Previous Positions

1993-2001, Associate Professor, Dept of Laboratory Medicine, University of Washington.
1987-1993, Assistant Professor, Dept of Laboratory Medicine, University of Washington.
1984-1987, Acting Instructor, Dept of Laboratory Medicine, University of Washington.

Research and Expertise

My primary interest is research on hemostasis and thrombosis. Hemostasis is a balance between factors that promote thrombus formation (the coagulation system, platelets), those that block thrombus formation (inhibitors such as antithrombin III or protein C/S) and those that promote removal of thrombi (fibrinolysis). Current projects in my laboratory include: 1) Regulation of thrombin generation, fibrin formation and fibrin removal from the vascular system. This project utilizes a combination of hemostatic marker measurements in humans to evaluate the effects of adrenergic agonists, exercise, endurance training, cardiopulmonary bypass and other stimuli on hemostasis in combination with a kinetic model of the circulatory regulation of hemostasis, 2) new assays for the detection of hemostatic and thrombotic abnormalities: evaluation of fibrinolytic assays and thrombotic markers for assessing the risk of arterial thrombosis (myocardial infarction), post-operative venous thrombosis, and hemorrhage during and after surgical procedures (particularly cardiopulmonary bypass). For more information on modeling hemostasis visit our website:

Hemostasis Simulation Web Project

http://depts.washington.edu/labweb/dept/staff/bios/hemostas/index.html

Other Web Links

COS Website: http://myprofile.cos.com/chandlew68

Publications

1. Chandler WL, Lloyd LB, Farrow MM, Burnham RR, Eyring EM. Titanium corrosion by a hot perfluoropolyether. Corrosion 1980;36:152-5.

2. Lloyd LB, Burnham RK, Chandler WL, Eyring EM, Farrow MM. Fourier transform photoacoustic visible spectroscopy of solids and liquids. Analytical Chem 1980;52:1595-98.

3. Gnepp DR, Chandler WL, Hyams V. Primary Kaposi's sarcoma of the head and neck. Ann Int Med 1984;100:107-14.

4. Longstreth WT, Clayson KJ, Chandler WL, Sumi SM. Cerebrospinal fluid creatine kinase activity and neurologic recovery after cardiac arrest. Neurology 1984;34: 834-7.

5. Chandler WL, Clayson KJ, Longstreth WT, Fine JS. Creatine kinase isoenzymes in cerebrospinal fluid and brain. Clin Chem 1984;30:1804-6.

6. Gnepp DR, Chandler WL. Tissue Culture of human and canine thoracic duct endothelium. In Vitro 1985;21:200-6.

7. Chandler WL, Schmer G. Evaluation of a new dynamic viscometer for measuring the viscosity of whole blood and plasma. Clin Chem 1986;32:505-7.

8. Chandler WL, Clayson KJ, Fine JS, Longstreth WT. Mitochondrial and MB isoenzymes of creatine kinase in cerebrospinal fluid from patients with hypoxic-ischemic brain damage. Am J Clin Pathol 1986;86:533-7.

9. Chandler WL, Clayson KJ, Fine JS. Comparison of solutions for extracting CK, AK and LD from brain samples. Clin Chem 1987;33:2304.

10. Chandler WL, Fine JS, Emery M, Weaver D, Reichenbach DR, Clayson KJ. Creatine kinase, adenylate kinase and lactate dehydrogenase in normal canine brain. Stroke 1988;19:251-5.

11. Chandler WL, Solomon DD, Hu CB, Schmer G. Estimation of surface bound heparin activity: a comparison of methods. J Biomed Mat Res 1988;22:497-508.

12. Whitten RO, Chandler WL, Thomas MGE, Clayson KJ, Fine JS. Survey of a-amylase activity and isoamylases in autopsy tissue. Clin Chem 1988;34:1552-5.

13. Whitten RO, Chandler WL, Thomas MGE, Clayson KJ, Fine JS. Three methods compared for isoamylase separation in tissue homogenates. Clin Chem 1988;34:1556-60.

14. Angleton P, Chandler WL, Schmer G. Diurnal variation in tissue-plasminogen activator and its rapid inhibitor. Circulation 1989;79:101-6.

15. Chandler WL, Schmer G, Stratton JR. Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in plasma. J Lab Clin Med 1989;113:362-71.

16. Chandler WL, Loo SC, Nguyen SV, Schmer G, Stratton JR. Standardization of the measurement of plasminogen activator inhibitor type 1 (PAI-1) in human plasma. Clin Chem 1989;35:787-793.

17. Chandler WL, Mornin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990;58:1-12.

18. Klauser RJ, Schmer G, Chandler WL, Muller W. Consumption of complement and activation of human neutrophils by an artificial immune complex: polyacrylic acid-IgG-polymer. Biochem Biophys Acta 1990;1052:408-415.

19. Chandler WL, Trimble SL, Loo SC, Mornin D. The effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex. Blood 1990;76:930-937.

20. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB. The effects of physical conditioning on fibrinolytic variables and fibrinogen in young and older healthy adults. Circulation 1991;83:1692-1697.

21. Burns MW, Chandler WL, Kreiger JN. Adenocarcinoma of rete testis, role of inguinal orchiectomy plus retroperitoneal lymph node dissection. Urology 1991;6:571-573.

*22. Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost 1991;66:321-328.

23. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB, Stratton JR. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Amer Coll Cardiol 1992;19:1412-1420.

24. Chandler WL, Loo SC, Mornin D. Adrenergic stimulation of regional plasminogen activator release in rabbits. Thromb Haemost 1992;68:545-549.

25. Chandler WL, Levy WC, Veith RC, Stratton JR. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion and endurance training. Blood 1993;81:3293-3302.

26. Chandler WL, Stratton JR. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Amer J Clin Pathol 1994;102:248-252.

27. La Spada AR, Skålhegg BS, Henderson R, Schmer G, Pierce R, Chandler WL. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Eng J Med 1995;333:494-497.

28. Davis CD, Chandler WL. Thromboelastography for the prediction of bleeding after transplant renal biopsy. J Amer Soc Nephrol 1995;6:1250-1255.

29. Chandler WL, Fitch JCK, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess BD. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995;74:1293-1297.

*30. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of t-PA and u-PA secretion, clearance and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995;92:2984-2994.

31. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1995;9:168-73.

32. Chandler WL, Schwartz RS, Stratton JR, Vitiello MV. Effects of endurance training on the circadian rhythm of fibrinolysis in men and women. Med Sci Sports Exer 1996;28:647-655.

33. Spiess BD, Gernsheimer T, Vocelka C, Chandler WL, Benak A, Joy JV, Wright I, Hofer B. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. J Cardiothor Vasc Anesth 1996;10:918-921.

34. Tirschwell DL, Longstreth WT, Rauch-Matthews ME, Chandler WL, Rothstein T, Wray L, Eng LJ, Fine J, Copass MK. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest. Neurology 1997; 48:352-357.

*35. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997;96:761-768.

36. Speiss BD, Wall MH, Gillies BS, Fitch JCK, Soltow LO, Chandler WL. A comparison of thromboelastography with heparinase or protamine sulfate added in-vitro during heparinized cardiopulmonary bypass. Thromb Haemost 1997;78:820-826.

37. Van Norman GA, Gernsheimer T, Chandler WL, Cochran RP, Spiess B. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin III administration for acquired antithrombin III deficiency. J Cardiothor Vasc Anesth 1997;6:760-763.

38. Vaezy S, Martin R, Schmiedl U, Caps M, Taylor S, Beach K, Carter S, Kaczkowski P, Keilman G, Helton S, Chandler W, Mourad P, Rice M, Roy R, Crum L. Liver hemostasis using high intensity focused ultrasound. Ultrasound in Medicine and Biology 1997;23:1413-1420.

39. Meissner MH, Chandler WL, Nicholls, SC. Coagulopathy after ruptured abdominal aortic aneurysm. Vascular Surgery 1997;31:727-736.

40. Crookston KP, Henderson R, Chandler WL. False negative factor V Leiden assay following allogenic stem cell transplant. Brit J Haematol 1998;100:600-602.

41. Spiess BD, Vocelka C, Cochran RP, Soltow L, Chandler WL. Heparin coated bypass circuits, Carmeda®, suppresses the release of tissue plasminogen activator during coronary artery bypass graft surgery. J Cardiothor Vasc Anesth 1998;12:299-304.

42 Rosoff JD, Soltow LO, Vocelka CR, Schmer G, Chandler WL, Cochran RP, Kunzelman KS, Speiss BD. A second generation blood substitute (perfluorodichlorooctane emulsion) does not activate compliment during an ex vivo circulation model of bypass. J Cardiothor Vasc Anesth 1998;12:397-401.

43. Caps MT, Meissner MH, Tullis MJ, Pollisar NL, Manzo RA, Zierler BK, Chandler WL, Strandness DE Jr. Venous Thrombus Stability During Acute Phase of Therapy. Vascular Medicine 1999; 4: 9-14.

44. Poliachik SL, Chandler WL, Mourad PD, Bailey M, Bloch S, Cleveland RO, Kaczkowski P, Keilman G, Porter T, Crum LA. Effect of high-intensity focused ultrasound on whole blood with and without microbubble contrast agent. Ultrasound Med Biol 1999;23:1413-1420.

45. Coplin WM, Longstreth WT Jr, Lam AM, Chandler WL, Mayberg TS, Fine JS, Winn HR. Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage. Arch Neurol 1999;56:1348-52

46. Van Norman GA, Patel MA, Robledo J, Simmons E, Chandler WL, Vocelka C. Effect of hemofiltration on aprotinin activity in patients undergoing cardiopulmonary bypass. J Cardiothor Vasc Anesth 2000;46:38-46.

47. Crookston KP, Marsh CL, Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator during orthotopic liver transplantation. Blood Coag Fibrinolysis 2000;11:79-88.

48. Chandler WL, Jascur ML, Henderson PJ. Measurement of different forms of tissue plasminogen activator in plasma. Clin Chem 2000;46:38-46.

49. Cuignet OY, Wood BL, Chandler WL, Spiess BD. A second generation blood substititute perfluorodichlorooctane emulsion) generates spurious elevations in platelet counts from automated hematology analyzers. Anesth Anal 2000;90:517-522.

*50. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000;30:204-218.

51. Chandler WL, Patel M, Gravelle L, Soltow L, Lewis K, Bishop PD, Spiess BD Factor XIIIA and Clot Strength after Cardiopulmonary Bypass. Blood Coag Fiblysis 2001;12:101-108.

52. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate and hemostatic effects of triphasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001;63:1-11.

53. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome. Pediatr Res 2001;49: 653-659

54. Sprouse JT, Wong CS, Chandler WL, Williams GD, Watkins SL, Tarr PI. Thrombogenic alleles, Escherichia coli O157:H7 infections, and hemolytic uremic syndrome. Blood Coag Fiblysis 2001;12:283-288

55. Poliachik SL, Chandler WL, Mourad PD, Ollos RJ, Crum LA. Activation, aggregation and adhesion of platelets exposed to high-intensity focused ultrasound. Ultrasound Med Biol. 2001; 27:1567-76.

*56. Chandler WL, Jelacic S, Boster, DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Eng J Med 2002;346:23-32.

57. Diabetes Prevention Program Research Group (see appendix). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002;346:393-403.

58. Aldea GS, Soltow LO, Chandler WL, Triggs CM, Vocelka CR, Crockett GI, Shin YT, Curtis WE, Verrier ED. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-755.

59. Meissner MH, Zierler BK, Bergelin RO, Chandler WL, Manzo RA, Strandness DE. Coagulation, fibrinolysis and recanalization after acute deep venous thrombosis. J Vasc Surg 2002;35:278-285.

Reviews, Letters to the Editor

1. Owen JD, Chandler WL, Eyring EM. Sickle hemoglobin and erythrocyte membrane permeability. Blood (letter) 1977;50:347-8.

2. Chandler WL, Fine JS, Clayson KJ. Abbreviations for mitochondrial creatine kinase. Clin Chem (letter) 1986;32:236.

3. Chandler WL, Clayson KJ, Fine JS, Longstreth WT Jr. Creatine kinase in CSF following acute stroke. Arch Neurol (letter) 1987;44:471-2.

4. Schmer G, Chandler WL. Enzyme reactors: achievements, problems, future perspectives. In: Bambauer R et al., editor: Therapeutic plasma exchange and selective plasma separation. New York, 1987, Schattauer, p 437-442.

5. Schmer G, Chandler WL. Enzyme reactors for the removal of amino acids from plasma. Meth Enz 1988;137:479-491.

6. Fine JS, Chandler WL, Clayson KJ. Estimation of brain lesion size based on quantifying CK-BB in Serum. Clin Chem (letter) 1989;35:2018-9.

7. Chandler WL. Cerebrospinal Fluid Creatine Kinase. Clin Chem 1990;30:1-4 (Check Sample CME program).

8. Chandler WL, Loo SC. Lipoprotein(a) does not show circadian variations. Thromb Haemost (letter) 1990;63:151.

9. Chandler WL. Treatment of septic shock associated thrombosis. J Lab Clin Med 1991;118:513-514 (editorial).

10. Chandler WL, Fine JS. Emergency department stat test turnaround times. Arch Pathol Lab Med (letter) 1992;116:898.

11. Rodgers GM, Chandler WL. Laboratory and clinical aspects of inherited thrombotic disorders. Amer J Hematol 1992;41:113-122.

12. Chandler WL. The thromboelastograph and the thromboelastograph technique. Sem Thromb Hemostas 1995;21(Suppl 4):1-6.

13. Chandler W. The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential? J Cardiovasc Pharm 1996;27(Suppl 1):S63-S68.

14. Chandler WL. The human fibrinolytic system. Crit Rev Onc Hem 1996;24:27-45.

15. Tirschwell DL, Chandler WL, Longstreth WT Jr. Cerebral hypoxia after cardiopulmonary resuscitation Lancet (letter) 1999;353:750

16. Vaezy S, Martin R, Goldman B, Chi E, Chandler WL, Kaczkowski P, Crum L. Biological mechanisms of acoustically-induced hemostasis. IEEE Ultras Symp 1999;2:1401-1404.

17. Crum LA, Beach K, Carter S, Chandler W, Curra F, Kaczkowski P, Keilman G, Khokhlova V, Martin R, Mourad P, and Vaezy S. Acoustic Hemostasis in Lauterborn W and Kurz T, eds, Nonlinear Acoustics at the Turn of the Millennium: ISNA 15, Am. Inst. of Physics (New York), pp. 13-22 (2000).

18. Chandler WL. The fibrinolytic response during cardiopulmonary bypass - pro or anticoagulant? In: Ed: Spiess BD ed, The relationship between coagulation, inflammation and Endothelium, Society of Cardiothoracic Anesthesia monograph. Baltimore Lippincott, 2000:147-163.

19. Nicholls SC, Hoffer EK, Chandler WL. Thrombolysis failure: a role for plasminogen activator inhibitor type I (PAI-1). Brit J Haematol (letter) 2001;113:559-560.

20. Spiess BD, Chandler WL. The genetic basis of procoagulant and fibrinolytic perioperative adverse events.Bailliere's Best Practice Research Clinical Anaesthesiology 2001;15:195-11.

21. Chandler WL, Velan T. ACM4WB - An advanced whole body circulatory model in Anderson G and Katzper M eds, Simulation in the Health and Medical Sciences 2001, Soc Comp Simul International (San Diego), pp 91-96 (2001).

22. Velan T, Chandler WL. A multilevel integrated simulation of coagulation in vivo (SIM COAG) in Anderson JG and Katzper M eds, Simulation in the Health and Medical Sciences 2001, Soc Comp Simul International (San Diego), pp 115-120 (2001).

23. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Archiv Pathol Lab Med in press (2002)

Keywords

hemostasis, thrombosis, fibrinolysis

Last updated: 6/22/00